DODAP
Based on 3 publication(s) in Google Scholar
DODAP is a cationic lipid utilized as the lipid component in liposomes (pKa = 5.59 in TNS binding tests). DODAP is employed for encapsulating siRNA and delivering immunostimulated chemotherapeutic agents both in vitro and in vivo. DODAP holds great promise for research in vaccines and inflammation.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.65%
- CAS No.: 127512-29-2
- 화학식: C41H77NO4
- 분자량:648.05
-
보관:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Lipid Compound Library
HY-L043
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Liposome Library
HY-L214
-
Ionizable Lipid Compound Library
HY-L251
Publications Citing Use of MedChemExpress (MCE) DODAP
More
Customer Validation & Images
-
Bio/Physico-chemical Assay
Biological Activity
DODAP (0.25-2 ng/µL, 24 h) has the ability to target the spleen[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293 cells
-
Concentration:0.25 ng/µL, 0.5 ng/µL, 1 ng/µL, 2 ng/µL
-
Incubation Time:24 h
-
Result:Had almost undetectable expression consistent with a TNS binding assay pKa of 5.62, although expression with this pKa has been observed in DODAP targeting the spleen. DODAP also showed heterogeneous ultrastructural features that were expected to reduce potency.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:female Balb/c mice[1]
-
Dosage:100 µg/mL
-
Administration:Intravenous injection (i.v.), Intramuscular injection (i.m.),4 h
-
Result:Treatment resulted that a less negatively charged DODAP was more efficient in vitro and in vivo intramuscular injection, while for Intravenous injection administration, a more negative DODAP that was passively targeted through Apo-E absorption was more efficient for hepatocyte targeting.
Chemical Information
-
CAS No. 127512-29-2
-
Appearance Liquid (Density: 0.916 g/cm3)
-
분자량 648.05
-
화학식 C41H77NO4
-
Color Colorless to light yellow
-
SMILES
CCCCCCCC/C=C\CCCCCCCC(OC(CN(C)C)COC(CCCCCCC/C=C\CCCCCCCC)=O)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nature
2026 Jun 8. PMID: 42259916 -
J Control Release
Direct structural investigation of pH responsiveness in mRNA lipid nanoparticles: Refining paradigms. [Abstract]2025 May 20:113848. PMID: 40404049
DODAP purchased from MedChemExpress. Usage Cited in: J Control Release. 2025 May 20:113848. [Abstract]
Correlation length as a function of pH, calculated from the peak width (FWHM). While DODAP and DODMA LNPs show a decrease in correlation length, the more potent lipids maintain their long-range order.
-
bioRxiv
2026 May 9:2026.05.08.723607. PMID: 42146678
용액&용해도
Ethanol : ≥ 100 mg/mL (154.31 mM)
DMSO : 100 mg/mL (154.31 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.86 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (3.86 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Carrasco MJ, et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun Biol. 2021 Aug 11;4(1):956. [Content Brief]
[2]. Dabbas S, et al. Importance of the liposomal cationic lipid content and type in tumor vascular targeting: physicochemical characterization and in vitro studies using human primary and transformed endothelial cells. Endothelium. 2008;15(4):189-201. [Content Brief]
[3]. Hamzah J, et al. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol. 2009;183(2):1091-1098. [Content Brief]
[4]. Liu Q, et al. Biotinylated cyclen-contained cationic lipids as non-viral gene delivery vectors. Chem Biol Drug Des. 2013;82(4):376-383. [Content Brief]
[5]. Mendonça LS, et al. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem. 2010 Jan;21(1):157-68. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 1.5431 mL | 7.7155 mL | 15.4309 mL | 38.5773 mL |
| 5 mM | 0.3086 mL | 1.5431 mL | 3.0862 mL | 7.7155 mL | |
| 10 mM | 0.1543 mL | 0.7715 mL | 1.5431 mL | 3.8577 mL | |
| 15 mM | 0.1029 mL | 0.5144 mL | 1.0287 mL | 2.5718 mL | |
| 20 mM | 0.0772 mL | 0.3858 mL | 0.7715 mL | 1.9289 mL | |
| 25 mM | 0.0617 mL | 0.3086 mL | 0.6172 mL | 1.5431 mL | |
| 30 mM | 0.0514 mL | 0.2572 mL | 0.5144 mL | 1.2859 mL | |
| 40 mM | 0.0386 mL | 0.1929 mL | 0.3858 mL | 0.9644 mL | |
| 50 mM | 0.0309 mL | 0.1543 mL | 0.3086 mL | 0.7715 mL | |
| 60 mM | 0.0257 mL | 0.1286 mL | 0.2572 mL | 0.6430 mL | |
| 80 mM | 0.0193 mL | 0.0964 mL | 0.1929 mL | 0.4822 mL | |
| 100 mM | 0.0154 mL | 0.0772 mL | 0.1543 mL | 0.3858 mL |
DODAP Related Classifications
HY-130751 Related Classifications
Powered by Bioz